Atherothrombotic Outcomes After Sodium‐Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients With Type 2 Diabetes: A Territory‐Wide Retrospective Cohort Study
SGLT2 inhibitors in patients with diabetes were independently associated with reduction in atherothrombotic major adverse cardiovascular events, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and incident dialysis, compared with DPP-4 inhibitors.
Authors
- Wai Ching Sin (ORCID: https://orcid.org/0000-0002-9151-6189)
- Andrew Kei‐Yan Ng (ORCID: https://orcid.org/0000-0002-5553-016X)
- April Ip (ORCID: https://orcid.org/0000-0002-7429-8167)
- Pauline Yeung Ng (ORCID: https://orcid.org/0000-0001-6671-5963)
- Kai‐Hang Yiu
Institutions
- Chinese University of Hong Kong (HK)
- Queen Mary Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1161/jaha.124.037207
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- Sanming Project of Medicine in Shenzhen